JAGSONPAL PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of JAGSONPAL PHARMACEUTICALS have increased by 6.89% YoY .
The Earnings Per Share (EPS) of JAGSONPAL PHARMACEUTICALS has decreased by -22.90 % YoY. |
||
JAGSONPAL PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 507789|NSE : JAGSNPHARM]
| Standalone | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹287 Cr | ₹269 Cr | ₹209 Cr | ₹237 Cr | ₹218 Cr |
| Expenses | ₹229 Cr | ₹218 Cr | ₹186 Cr | ₹203 Cr | ₹193 Cr |
| Operating Profit (Excl OI) | ₹58 Cr | ₹51 Cr | ₹23 Cr | ₹34 Cr | ₹25 Cr |
| Other Income | ₹12 Cr | ₹8.19 Cr | ₹9.28 Cr | ₹5.73 Cr | ₹3.43 Cr |
| Interest | ₹1.03 Cr | ₹0.96 Cr | ₹0.81 Cr | ₹0.41 Cr | ₹0.29 Cr |
| Depreciation | ₹9.44 Cr | ₹8.13 Cr | ₹1.66 Cr | ₹1.21 Cr | ₹1.53 Cr |
| Profit Before Tax | ₹58 Cr | ₹70 Cr | ₹30 Cr | ₹35 Cr | ₹27 Cr |
| Profit After Tax | ₹43 Cr | ₹55 Cr | ₹22 Cr | ₹27 Cr | ₹19 Cr |
| Earnings Per Share (Rs) | ₹6.43 | ₹8.34 | ₹8.50 | ₹10.20 | ₹7.20 |
| PAT Margin (%) | 14.15 | 19.65 | 10.01 | 10.39 | 7.78 |
| ROE(%) | 18.19 | 28.51 | 14.02 | 18.89 | 15.28 |
| ROCE(%) | 22.69 | 33.14 | 17.72 | 24.15 | 21.23 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 1,602.5 Cr |
| Revenue (TTM) | : | ₹ 293.8 Cr |
| Net Profit(TTM) | : | ₹ 45.5 Cr |
| EPS (TTM) | : | ₹ 6.9 |
| P/E (TTM) | : | 35.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| JAGSONPAL PHARMACEUTICALS | 7% | 0.9% | -7.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | -3.3% | 13.1% |
| DIVIS LABORATORIES | 2.6% | 10.8% | 57.3% |
| TORRENT PHARMACEUTICALS | 2.7% | 0.3% | 39.6% |
| CIPLA | 2.4% | -1.1% | -12.6% |
| DR REDDYS LABORATORIES | 2.5% | 0.8% | -8.5% |
| MANKIND PHARMA | 6.8% | 4.6% | -6.7% |
| LUPIN | -2.2% | -3.5% | 2.6% |
| ZYDUS LIFESCIENCES | 2.3% | 4.4% | 11.6% |
JAGSONPAL PHARMACEUTICALS Revenues
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | 6.89 % |
| 5 Yr CAGR | 7.19 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹287 Cr | 6.89 | |
| Mar2025 | ₹269 Cr | 28.76 | |
| Mar2024 | ₹209 Cr | -11.83 | |
| Mar2023 | ₹237 Cr | 8.79 | |
| Mar2022 | ₹218 Cr | - | |
JAGSONPAL PHARMACEUTICALS Operating Profit
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | 13.71 % |
| 5 Yr CAGR | 23.42 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹58 Cr | 13.71 | |
| Mar2025 | ₹51 Cr | 121.40 | |
| Mar2024 | ₹23 Cr | -32.46 | |
| Mar2023 | ₹34 Cr | 36.47 | |
| Mar2022 | ₹25 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 6.37 % |
| 5 Yr CAGR | 15.15 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 20.22% | 6.37 | |
| Mar2025 | 19.01% | 72.04 | |
| Mar2024 | 11.05% | -23.42 | |
| Mar2023 | 14.43% | 25.48 | |
| Mar2022 | 11.5% | - | |
JAGSONPAL PHARMACEUTICALS Profit After Tax
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -22.18 % |
| 5 Yr CAGR | 22.95 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹43 Cr | -22.18 | |
| Mar2025 | ₹55 Cr | 146.45 | |
| Mar2024 | ₹22 Cr | -15.94 | |
| Mar2023 | ₹27 Cr | 41.72 | |
| Mar2022 | ₹19 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -27.99 % |
| 5 Yr CAGR | 16.13 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 14.15 % | -27.99 | |
| Mar2025 | 19.65 % | 96.30 | |
| Mar2024 | 10.01 % | -3.66 | |
| Mar2023 | 10.39 % | 33.55 | |
| Mar2022 | 7.78 % | - | |
JAGSONPAL PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -22.90 % |
| 5 Yr CAGR | -2.79 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹6.43 | -22.90 | |
| Mar2025 | ₹8.34 | -1.88 | |
| Mar2024 | ₹8.50 | -16.67 | |
| Mar2023 | ₹10 | 41.67 | |
| Mar2022 | ₹7.20 | - | |
JAGSONPAL PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -31.53 % |
| 5 Yr CAGR | 1.68 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 22.69% | -31.53 | |
| Mar2025 | 33.14% | 87.02 | |
| Mar2024 | 17.72% | -26.63 | |
| Mar2023 | 24.15% | 13.75 | |
| Mar2022 | 21.23% | - | |
JAGSONPAL PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹242.8 |
| Current MarketCap | : | ₹ 1,602.5 Cr |
| Updated EOD on | : | Sep 25,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JAGSONPAL PHARMACEUTICALS | 7% |
0.9% |
-7.3% |
| SENSEX | -0.5% |
-4.8% |
-11% |
JAGSONPAL PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 0.3% | 1.4% | 14.3% |
No NSE index found
You may also like the below Video Courses
FAQ about JAGSONPAL PHARMACEUTICALS Financials
How the annual revenues of JAGSONPAL PHARMACEUTICALS have changed ?
The Revenues of JAGSONPAL PHARMACEUTICALS have increased by 6.89% YoY .
How the Earnings per Share (EPS) of JAGSONPAL PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of JAGSONPAL PHARMACEUTICALS has decreased by -22.90 % YoY .
Check out Intrinsic Value of Peers of JAGSONPAL PHARMACEUTICALS
Compare Stock Analytics of Peers of JAGSONPAL PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
